News

No img

Tevard Reports Data on Suppressor tRNA Therapy Restoring Full-Length Dystrophin in Duchenne Muscular Dystrophy Model

-Promising Study Results Featured During Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting- Boston, MA — Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, presented preclinical data demonstrating the potential of its tRNA therapy in Duchenne Muscular Dystrophy […]

Leer Más
No img

Tevard to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model

Oral Presentation at the Upcoming American Society of Gene and Cell Therapy Annual Meeting Boston, MA — Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, will present preclinical data supporting the potential of its tRNA therapy in Duchenne Muscular Dystrophy (DMD). The study demonstrated that […]

Leer Más
No img

Tevard Biosciences to Move Corporate Headquarters to Lilly Gateway Labs in Boston’s Seaport

August 13, 2024, Cambridge, MA — Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced that it will be moving its corporate headquarters to Lilly Gateway Labs (LGL) located in the Seaport District in Boston. Tevard was selected to join the LGL community […]

Leer Más
No img

Industry Veteran and RNA Therapeutics Expert, John Maraganore, Joins Tevard Biosciences as Strategic Advisor and Board Observer

June 24, 2024, Cambridge, MA — Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of John Maraganore, Ph.D., as a Strategic Advisor and Board Observer. Dr. Maraganore brings a wealth of experience and knowledge in the field of RNA therapeutics. […]

Leer Más
No img

Tevard Biosciences appoints Dr. Gregory Robinson as Chief Scientific Officer

Tevard Biosciences, Inc., the pioneer of tRNA-based therapies and other mRNA-modulating treatments for genetic diseases, announced today that it has appointed Dr. Gregory Robinson as Chief Scientific Officer. Dr. Robinson brings extensive leadership experience with research and clinical development. “Dr. Robinson has a long track record of success in translating innovative science into new medicines […]

Leer Más
No img

Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy

Tevard Biosciences, Inc., the pioneer of tRNA-based therapies for severe genetic diseases, today announced a four-year global research collaboration with Vertex Pharmaceuticals Incorporated aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD) caused by nonsense mutations with options to expand into additional muscular dystrophies and a second indication. The agreement provides […]

Leer Más
No img

Tevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board

Leading tRNA researcher joins Tevard’s efforts to transform tRNAs into novel treatments for serious genetic diseases CAMBRIDGE, Mass., August 3, 2022 Tevard Biosciences, the pioneer of tRNA-based therapies for severe genetic diseases, today announced the appointment of leading tRNA scientist Zoya Ignatova, Ph.D, to its scientific advisory board. “Dr. Ignatova’s work has profoundly impacted our […]

Leer Más
No img

Tevard CEO Awarded Henri Termeer Fellowship

The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, has named Tevard CEO and co-founder Daniel Fischer as a member of the Class of 2022 Henri Termeer Fellows. The Henri Termeer Fellowship honors “emerging leaders within the life science industry who have shown initial promise […]

Leer Más
No img

Tevard Biosciences licenses mRNA Amplifier technology from Johns Hopkins University

New platform provides additional avenue for treating severe genetic diseases, joins Tevard’s tRNA-based platforms in broadly applicable suite of technologies   Tevard Biosciences, the pioneer of tRNA-based treatments for severe genetic diseases, today announced an agreement to exclusively license “mRNA Amplifier” technology from the Johns Hopkins University. The technology will help form the basis of […]

Leer Más
No img

Tevard Biosciences Appoints Paul Schimmel, Susan Ackerman, and Nicholas Ingolia to Its Scientific Advisory Board

Researchers’ deep expertise in tRNAs and gene translation bolsters Tevard’s efforts to address a broad range of genetic diseases CAMBRIDGE, Mass., March 9, 2022 Tevard Biosciences, the pioneer of tRNA-based treatments for severe genetic diseases, today announced the appointment of Paul Schimmel, Ph.D., Susan Ackerman, Ph.D., and Nicholas Ingolia, Ph.D., to its scientific advisory board. […]

Leer Más